Efficacy, symptoms, and safety of second-line PBC therapies: a network meta-analysis
Wenbin Zhao, Zhichao Wu, Qingyan Kou, Shengxian Qiao, Zhenyuan Liu, Xu Zhang · 2026
Read Efficacy, symptoms, and safety of second-line PBC therapies: a network meta-analysis by Wenbin Zhao, Zhichao Wu, Qingyan Kou, Shengxian Qiao, Zhenyuan Liu, Xu Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13547053.txt.
Description
Wenbin Zhao and co-authors rank second-line drugs for a slow liver disease that stops answering its first-line cure. Primary biliary cholangitis scars bile ducts, and many patients respond only in part to the standard acid drug. New drug families have crowded in fast, leaving doctors without a clear order of merit.
The team pools twelve trials with fifteen hundred forty patients in a network meta-analysis. Drugs span three families: PPAR agonists, an FXR agonist, and a bile acid blocker. On the standard response bar, bezafibrate ranked top by a wide margin. The strictest bar, full enzyme normalization, told a partly different story, as did itch relief scores. Safety tallies of serious harms complete the table. The ranking gives liver clinics a firmer basis for second-line picks.
Catalog record
| CREATOR | Wenbin Zhao, Zhichao Wu, Qingyan Kou, Shengxian Qiao, Zhenyuan Liu, Xu Zhang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |